Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
PJ Carter, V Quarmby - Nature Reviews Drug Discovery, 2024 - nature.com
Remarkable progress has been made in recent decades in engineering antibodies and
other protein therapeutics, including enhancements to existing functions as well as the …
other protein therapeutics, including enhancements to existing functions as well as the …
Evaluating the Immunogenicity Risk of Protein Therapeutics by Augmenting T Cell Epitope Prediction with Clinical Factors
Z Hu, P Wu, SJ Swanson - The AAPS Journal, 2025 - Springer
Protein-based therapeutics may elicit undesired immune responses in a subset of patients,
leading to the production of anti-drug antibodies (ADA). In some cases, ADAs have been …
leading to the production of anti-drug antibodies (ADA). In some cases, ADAs have been …